

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-170) TORIPALIMAB

PRONUNCIATION tor" ip a' li mab

THERAPEUTIC CLAIM Antineoplastic

CHEMICAL NAMES

1. Immunoglobulin G4, anti-(human programmed cell death protein 1) (human monoclonal JS001 γ 4-chain), disulfide with human monoclonal JS001 κ -chain, dimer (Source: CAS)
2. Immunoglobulin G4-kappa, anti-[*Homo sapiens* PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], monoclonal antibody; gamma4 heavy chain (1-452) [VH (*Homo sapiens* IGHV1- 46*01 (80.6%) -(IGHD)-IGHJ3*01 (92.9%)) [8.8.18] (1-125) -*Homo sapiens* IGHG4*01 (CH1 (126-223), hinge S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (126-452)], (139-219')-disulfide with kappa light chain (1'-219') [V-KAPPA (*Mus musculus* IGKV1-117*01 (93.0%)/*Homo sapiens* IGKV2-30*02 (88.0%) -*Homo sapiens* IGKJ2*01 (100%)) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01, Km3 A45.1 (158), V101 (196) (113'- 219')]; dimer (231-231":234-234")-bisdisulfide (Source : WHO PINN list 119)

STRUCTURAL FORMULA

Heavy chain

| | | | | | |
|------------|------------|------------|------------|------------|-----|
| QGQLVQSGAE | VKKPGASVKV | SCKASGYTFT | DYEMHWVRQA | PIHGLEWIGV | 50 |
| IESETGGTAY | NQKFKGRVTI | TADKSTSTAY | MELSSLRSED | TAVYYCAREG | 100 |
| ITTVATTYYW | YFDVWQGQTT | VTVSSASTKG | PSVFLAPCS | RSTSESTAAL | 150 |
| GCLVKDYFPE | PVTVSWNSGA | LTSGVHTFPA | VLQSSGLYSL | SSVVTVPSSS | 200 |
| LGTKTYTCNV | DHKPSNTKVD | KRVESKYGPP | CPPCPAPEFL | GGPSVFLFPP | 250 |
| KPKDTLMISR | TPEVTCVVVD | VSQEDPEVQF | NWYVDGVEVH | NAKTKPREEQ | 300 |
| FNSTYRVVSV | LTVLHQDNLN | GKEYKCKVSN | KGLPSSIEKT | ISKAKGQPRE | 350 |
| PQVYTLPPSQ | EEMTKNQVSL | TCLVKGFYPS | DIAVEWESNG | QPENNYKTP | 400 |
| PVLDSGGSFF | LYSRLTVDKS | RWQEGNVFSC | SVMHEALHNS | YTQKSLSLSL | 450 |
| GK | | | | | 452 |

Light chain

| | | | | | |
|------------|------------|-------------|------------|------------|------|
| DVVMTQSPLS | LPVTLGQPAS | ISCRSSQSIV | HSNGNTYLEW | YLQKPGQSPQ | 50' |
| LLIYKVSNR | SGVPDRFSGS | GSGTDFTLKI | SRVEAEDVGV | YYCFQGSHPV | 100' |
| LTFGQGTKLE | IKRTVAAPSV | FIFPPSDEQL | KSGTASVCL | LNNFYPREAK | 150' |
| VQWKVDNALQ | SGNSQESVTE | QDSKDYSTYSL | SSTLTLSKAD | YEKHKVYACE | 200' |
| VTHQGLSSPV | TKSFNRGEC | | | | 219' |

Disulfide bridges

| | | | | | |
|----------|--------------|---------|-------------|------------|---------------|
| 22-96 | 22''-96'' | 23'-93' | 23'''-93''' | 139'-199' | 139'''-199''' |
| 139-219' | 139''-219''' | 152-208 | 152''-208'' | 231-231''' | 234-234'' |
| 266-326 | 266''-326'' | 372-430 | 372''-430'' | | |

Glycosylation sites (N)

| | |
|-----|-------|
| 302 | 302'' |
|-----|-------|

MOLECULAR FORMULA

C₆₅₄₈H₁₀₁₀₄N₁₇₂₈O₂₀₅₄S₄₄ (peptide)

MOLECULAR WEIGHT

147.3 kDa

| | |
|----------------------------|------------------------------|
| TRADEMARK | None as yet |
| SPONSOR | TopAlliance Biosciences Inc. |
| CODE DESIGNATIONS | JS001, TAB001 |
| <u>CAS</u> REGISTRY NUMBER | 1924598-82-2 |
| UNII | 8JXN261VVA |
| WHO NUMBER | 10820 |

gbk